Business Wire

POSIFLEX-TECHNOLOGY

Share
Posiflex Launches Opera MT-6200 Series Mobile POS Tablet

Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, today announced its latest mobile POS tablet offering - the Opera MT-6200 Series, which explores mobility and efficiency with sleek, lightweight yet semi-rugged designs. It supports Android 13 with GMS Certification or Windows 11 IoT OS, available in both x86 and RISC variants. With screen sizes of 8" and 10.1", the series features dockability with a USB Type-C connector, allowing for fast power charging. Complemented by a variety of POS accessories to enhance functionality, they are designed to meet the demands of the mobile economy across various industries. This includes retail stores, hospitality, logistics, inventory/warehouse management, and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624392969/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Posiflex Opera MT-6200 Series Mobile POS Tablet (Photo: Business Wire)

Superior Durability for Tough Applications

Leveraging Posiflex's cutting-edge engineering excellence, the Opera MT-6200 Series achieves a harmonious balance between the conflicting demands of tablets. It combines a lightweight and thin design with high-performance computing and semi-rugged durability. Equipped with a Corning Gorilla III touch screen, a PCAP multi-touch TFT LCD with 300nits brightness. The tablet is ideal for heavy use in various environments with ease. To ensure durability, the series incorporates semi-rugged designs, including IP54 water and dust resistance. It can withstand drops from 1 meter (1.2 meters with a protective case) and features a unique anti-slip design, providing a secure grip during handheld use. These elements collectively make the Opera MT-6200 Series resilient against the challenges of daily use.

Efficient USB Type-C for Fast Charging

Fast power charging and power efficiency are also essential to support the superior mobility of POS tablets. The Opera MT-6200 Series features an IPX7 waterproof USB Type-C connector for docking and rapid power charging. This feature enhances the overall user experience, providing convenience and efficiency for on-the-go professionals in various business environments. In particular, the smart docking station has a special bracket for protection and convenient charging, but when the tablet is in a rubber protective case, it can be docked directly to the charger without removing the case.

Flexible Functions for Customizable User Experience

In addition to a built-in 2D scanner and NFC module, Opera MT-6200 Series tablets offer programmable buttons on both sides of the screen bezel for customizable functionality, allowing customization for your specific applications. Opera MT-6200 series leads the way with seamless connectivity, supporting WiFi 5/6 and Bluetooth 5.0/5.2, ensuring a superior and efficient user experience.

Wide Range of Accessories to Extend Functionality and Maximize Convenience

As one of the manufacturers in the world capable of producing a complete range of POS terminals and peripherals from a single source, Posiflex offers a wide range of optional accessories including fingerprint reader, MSR, shoulder strap, protective case with rotatable handheld strap, touch pen and more. The smart docking station is also equipped with a variety of I/O ports to extend the functions for stationary operations - all to maximize flexibility, user value and convenience.

About POSIFLEX Group

Posiflex Group is a global leading Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Software-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240624392969/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye